Skip to main content

Table 4 Kaplan–Meier estimates of overall survival by age group

From: Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease

 

No. at risk

Cumulative events/censored

Survival rate, %

(95% CI)

Children < 18 years (n = 33)

 At 0 months

33

0/0

100.0

(100.0, 100.0)

 At 3 months

21

10/2

69.2

(50.2, 82.1)

 At 6 months

17

13/3

59.1

(40.0, 73.9)

 At 9 months

14

16/3

48.7

(30.2, 64.8)

 At 12 months

12

18/3

41.7

(24.2, 58.4)

 At 24 months

6

20/8

35.4

(18.6, 52.7)

Adults ≥ 18 years (n = 123)

 At 0 months

123

1/0

99.2

(94.4, 99.9)

 At 3 months

74

44/6

63.5

(54.2, 71.4)

 At 6 months

54

63/7

47.0

(37.7, 55.7)

 At 9 months

47

69/7

41.6

(32.6, 50.4)

 At 12 months

39

76/10

35.4

(26.8, 44.1)

 At 24 months

17

84/30

30.3

(22.0, 39.1)

  1. CI, confidence interval